Market Cap 320.14M
Revenue (ttm) 3.48M
Net Income (ttm) -242.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,954.89%
Debt to Equity Ratio 0.00
Volume 35,900
Avg Vol 111,976
Day's Range N/A - N/A
Shares Out 11.49M
Stochastic %K 67%
Beta 0.52
Analysts Strong Sell
Price Target $38.75

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 489 9000
Address:
171 Oyster Point Boulevard, Suite 400, South San Francisco, United States
BuyoutBobby
BuyoutBobby Apr. 5 at 11:40 AM
$SRZN What Chatgpt thinks what 2026 could happen:
0 · Reply
BuyoutBobby
BuyoutBobby Apr. 2 at 6:43 PM
$SRZN another portfolio company of TCGX acquired by big pharma.
1 · Reply
wjmax
wjmax Mar. 31 at 7:41 PM
$SRZN $NWBO Here might be the reason that TCG and Baker Brothers have investment in $SRZN. For a potent tolerogenic DC vaccine targeting autoimmunity or transplant tolerance, activating the β-catenin arm of the Wnt pathway is one of the most well-validated and mechanistically coherent strategies available.
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 31 at 11:58 AM
$SRZN there is more research from AntlerA which should also apply to our WNT drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12330627/
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 29 at 5:01 PM
$SRZN there's a good chance that Merck wasn't the only company that wanted to acquire Eyebio. Merck won the bidding war and we don't know who lost it. But if they want another chance to get a WNT pipeline here we are with even better drugs.
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 28 at 12:12 PM
$SRZN the buying of TCGX also shows that they are ok with the MOA of the WNT drugs which seem to increase PDGFB signaling. The research was published March 17 so that could mean that TCG/TCGX knew about the mechanism of action already or they are ok with buying more even after knowing about it now.
0 · Reply
wjmax
wjmax Mar. 27 at 4:36 PM
$SRZN $NWBO Have$SRZN retailers realized how $SRZN's pipeline can be combined with $NWBO's DCVax? Is TCG the largest shareholder of $SRZN? TCG is also a large shareholder of $EIKN, the so-called 'Merck 2.0', which is developing TLR 7/8 agonist. TCG was also the large shareholder of Immune Design which owned TLR4 agonist and was acquired by Merck with $300M in cash after Roger Perlmutter, SVP from Merck convinced a large shareholder to sell. Roger Perlmutter is the CEO of $EIKN. It's all connected. https://www.fiercebiotech.com/biotech/anatomy-a-deal-how-merck-closed-immune-design-for-300m
1 · Reply
Quantumup
Quantumup Mar. 27 at 12:44 PM
H.C. Wainwright reiterated $OCUL Buy/$21 $KOD $EYPT $REGN RHHBY $SRZN Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2037510171836960935?s=20
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 27 at 7:13 AM
$SRZN i think the biggest tell is still the coordinated actions of TCG/TCGX or at least it looks like it is a coordinated action of them. So TCG terminated the related party deal and then they dissolved the company TCGFB. Surrozen wrote of the warrants we got from TCGFB(3,380,000 shares). Then TCG started buying shares of Surrozen from November until end of January. They ended the buying with the publication of a new SCHEDULE 13D/A filing on January 22. On January 26 Dr. Lin resigned from the board of directors. We don't really know why but the reason is not public so it could have created material non public informations for the involved people(TCG) Also on January 26 TCGX acquired a big block trade that could have been from the ATM sale of Surrozen. It is a bit questionable to help TCGX to load up shares especially if there is a buyout afterwards. Kinda like helping our insiders(TCG) to load up shares before a buyout but because they are not clearly insiders(TCGX) it could be ok.
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 27 at 6:44 AM
$SRZN Committee Composition was changed after the annual report again. This is the new one.
1 · Reply
Latest News on SRZN
Surrozen to Present at Upcoming Healthcare Investor Conference

Feb 25, 2026, 4:05 PM EST - 5 weeks ago

Surrozen to Present at Upcoming Healthcare Investor Conference


Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 25, 2025, 4:05 PM EST - 4 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences


Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs


Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results


Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results


Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 25, 2023, 10:02 AM EDT - 3 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript


Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results


Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports First Quarter 2022 Financial Results


Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results


BuyoutBobby
BuyoutBobby Apr. 5 at 11:40 AM
$SRZN What Chatgpt thinks what 2026 could happen:
0 · Reply
BuyoutBobby
BuyoutBobby Apr. 2 at 6:43 PM
$SRZN another portfolio company of TCGX acquired by big pharma.
1 · Reply
wjmax
wjmax Mar. 31 at 7:41 PM
$SRZN $NWBO Here might be the reason that TCG and Baker Brothers have investment in $SRZN. For a potent tolerogenic DC vaccine targeting autoimmunity or transplant tolerance, activating the β-catenin arm of the Wnt pathway is one of the most well-validated and mechanistically coherent strategies available.
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 31 at 11:58 AM
$SRZN there is more research from AntlerA which should also apply to our WNT drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12330627/
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 29 at 5:01 PM
$SRZN there's a good chance that Merck wasn't the only company that wanted to acquire Eyebio. Merck won the bidding war and we don't know who lost it. But if they want another chance to get a WNT pipeline here we are with even better drugs.
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 28 at 12:12 PM
$SRZN the buying of TCGX also shows that they are ok with the MOA of the WNT drugs which seem to increase PDGFB signaling. The research was published March 17 so that could mean that TCG/TCGX knew about the mechanism of action already or they are ok with buying more even after knowing about it now.
0 · Reply
wjmax
wjmax Mar. 27 at 4:36 PM
$SRZN $NWBO Have$SRZN retailers realized how $SRZN's pipeline can be combined with $NWBO's DCVax? Is TCG the largest shareholder of $SRZN? TCG is also a large shareholder of $EIKN, the so-called 'Merck 2.0', which is developing TLR 7/8 agonist. TCG was also the large shareholder of Immune Design which owned TLR4 agonist and was acquired by Merck with $300M in cash after Roger Perlmutter, SVP from Merck convinced a large shareholder to sell. Roger Perlmutter is the CEO of $EIKN. It's all connected. https://www.fiercebiotech.com/biotech/anatomy-a-deal-how-merck-closed-immune-design-for-300m
1 · Reply
Quantumup
Quantumup Mar. 27 at 12:44 PM
H.C. Wainwright reiterated $OCUL Buy/$21 $KOD $EYPT $REGN RHHBY $SRZN Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2037510171836960935?s=20
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 27 at 7:13 AM
$SRZN i think the biggest tell is still the coordinated actions of TCG/TCGX or at least it looks like it is a coordinated action of them. So TCG terminated the related party deal and then they dissolved the company TCGFB. Surrozen wrote of the warrants we got from TCGFB(3,380,000 shares). Then TCG started buying shares of Surrozen from November until end of January. They ended the buying with the publication of a new SCHEDULE 13D/A filing on January 22. On January 26 Dr. Lin resigned from the board of directors. We don't really know why but the reason is not public so it could have created material non public informations for the involved people(TCG) Also on January 26 TCGX acquired a big block trade that could have been from the ATM sale of Surrozen. It is a bit questionable to help TCGX to load up shares especially if there is a buyout afterwards. Kinda like helping our insiders(TCG) to load up shares before a buyout but because they are not clearly insiders(TCGX) it could be ok.
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 27 at 6:44 AM
$SRZN Committee Composition was changed after the annual report again. This is the new one.
1 · Reply
SocioCobb
SocioCobb Mar. 27 at 4:16 AM
$SRZN 👍
1 · Reply
SirBensonbot
SirBensonbot Mar. 27 at 3:02 AM
$SRZN long
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 26 at 6:15 PM
$SRZN over $300 million market cap is hard to explain for a preclinical company. What could be the reason for such a high value apart from the potential buyout?
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 26 at 2:52 PM
$SRZN more competition from Kodiak Sciences. https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-positive-topline-results-glow2-second/
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 26 at 7:10 AM
$SRZN they are buying more and more shares. Seems like TCGX is not considered an insider by Surrozen because they never really stopped buying shares before the annual report. That could mean that they have strong information barriers and that insider informations from TCG are not going to TCGX. That could also mean that TCGX can buy shares as long as they want even if Surrozen is already in negotiations for a buyout because TCGX wouldn't get that information.
2 · Reply
BuyoutBobby
BuyoutBobby Mar. 24 at 6:51 PM
$SRZN the annual report made Surrozen stronger than ever from a negotiation strength perspective. They now have the following money raising possibilities. New $50 million ATM plus $200 million shelf registration plus second tranche of the 2025 offering(around $100 million). They also have TCG supporting Surrozen(that big block trade locked like it came from the ATM). So from a financial strength they couldn't be in a better position. Boehringer just reached a SZN-413 milestone which means the WNT drug which is the same as the WNT sequence of SZN-8141/8143 is probably safe enough to move into phase 1 trials. BI now knows more about our drugs and in combination with Re-Vana's sustained release technology it could be even better. They have to decide if it really makes sense to start clinical trials with SZN-413 if SZN-8141 is better and nearly at the same development stage. That decision should happen this year and Surrozen is perfectly prepared for it.
0 · Reply
Scorpole
Scorpole Mar. 24 at 2:45 PM
$SRZN I don’t know about you guys, but I can’t read anything in the ER, that SP should drop 5%. So the drop for me it is only about Trump and the war. I have bought another 1000 at 24 today.
1 · Reply
Quantumup
Quantumup Mar. 24 at 12:59 PM
H.C. Wainwright⬆️ $SRZN PT to $36/reiterated at Buy. $EYPT $OCUL $FDMT $REGN RHHBY KOD Here's what H.C. Wainwright had to say in its note: https://x.com/Quantumup1/status/2036427176845640179?s=20
0 · Reply
Quantumup
Quantumup Mar. 19 at 12:24 PM
RBC Capital⬆️ $FDMT's PT to $35 from $32 and reiterated at Outperform after FDMT reported Q4 results. $OCUL $EYPT $SRZN REGN RHHBY KOD $OTSKY Here's what RBC Capital had to say in its note::: https://x.com/Quantumup1/status/2034605824538988952?s=20
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 19 at 9:27 AM
$SRZN kinda interesting so TCGX sold over 6 million Ocular Therapeutix shares in Q4 2025 while TCG terminated the related party deal with Surrozen in Q4 2025 and then started to buy a lot of shares of Surrozen. TCGX also started to buy shares of Surrozen in Q1 2026. So this seems like a bigger rotation of TCG from one ophthalmology player into another one. While Boehringer Ingelheim is looking for new ophthalmology drugs that perfectly fit our profile. And then new research is published that could indicate that Ocular Therapeutix drug axitinib(PDGF inhibition) could be worse than WNT drugs(PDGF activation).
1 · Reply
BuyoutBobby
BuyoutBobby Mar. 18 at 10:26 PM
$SRZN TCG Crossover was a shareholder of Ocular Therapeutix with around 6 million shares but last reported on February 17 they published that they own 0 shares of OCUL now. Kinda interesting. They were loading Surrozen while selling Ocular.
0 · Reply
BuyoutBobby
BuyoutBobby Mar. 18 at 2:37 PM
$SRZN i don't know if this is already known by Surrozen or Boehringer Ingelheim but this PDGFB signaling could be a huge thing. https://www.researchgate.net/publication/376389449_Role_of_endothelial_PDGFB_in_arterio-venous_malformations_pathogenesis
0 · Reply